CHI3L1关于长期鼻炎与鼻多元体的纤维解质系统失衡
Hyun-Woo Yang1, Joo-Hoo Park1, Jae-Min Shin2
1Upper Airway Chronic Inflammatory Diseases Laboratory, Korea University College of Medicine, Seoul, Republic of Korea.
Frontiers in immunology
|July 8, 2024
概括
慢性鼻炎 (CRS) 中的乙氨基基酸通过CHI3L1损害纤维解质系统,增加纤维素沉积. 向CHI3L1可能会减少CRS相关的胀,并提供新的治疗策略.
科学领域:
- 免疫学和炎症研究研究
- 分子生物学和遗传学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
背景情况:
- 慢性鼻炎 (CRS) 影响全球10%以上的成年人,具有明显的Th2/Th17内型.
- 乙性CRS (ECRS) 与组织重塑和纤维素分解受损有关.
- 了解乙素在CRS纤维素沉积中的参与对于治疗开发至关重要.
研究的目的:
- 为了研究埃索诺菲尔在CRS鼻组织中的纤维素沉积中的作用.
- 探索调节异性CRS中纤维素沉积的分子机制.
- 在ECRS中确定抑制纤维素沉积和的潜在治疗点.
主要方法:
- 在CRS组织中,对蛇家族和纤维溶解基因的基因表达分析 (GEO,NGS).
- 差异基因表达分析,KEGG和GO丰富用于途径识别.
- 测量PAI-1,t-PA,u-PA,u-PAR;通过细胞因子阵列和共同培养来评估乙氨基基基的影响.
主要成果:
- CRS组织表现出增加的PAI-1,u-PA和u-PAR,与降低的t-PA表达.
- 纤维解酶基因表达与Th2细胞因子正相关,不包括t-PA.
- 在纤维细胞和上皮细胞中,由埃索诺菲尔衍生的CHI3L1上调的PAI-1和下调的t-PA,通过CHI3L1抑制抑制效应.
结论:
- 基因酶-3样蛋白1 (CHI3L1) 通过破坏CRS中的纤维分解系统来促进纤维素沉积.
- 抑制CHI3L1代表了一种潜在的治疗策略,以减少ECRS中的纤维素沉积和.
- 向CHI3L1可能提供一种新的治疗方法,用于eosinophilic慢性鼻炎.
相关概念视频
01:30Epistaxis
144
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
144
01:23Chronic Pharyngitis
1.7K
Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
1.7K
01:16Clot Retraction and Fibrinolysis
5.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.4K
01:24Cystic Fibrosis: Management
154
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
154
01:17Drugs Used in Lower Respiratory Disorders: Overview
397
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
397